Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F1T13
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $105,362
Award facts
- Contract value 100% obligated
- $105,362.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $105,362.48 firm fixed-price delivery order to Amerisourcebergen Drug Corp (UEI: KABZK8W6PQT3) on January 6, 2026, with an ultimate completion date of January 7, 2026. The contract, which carries no set-aside designation, covers the supply of Repatha 140 mg/mL SureClick auto-injectors and will be performed at Amerisourcebergen's corporate office location in Conshohocken, Pennsylvania. Repatha is a PCSK9 inhibitor used to reduce cholesterol levels and lower cardiovascular risk in patients with high cholesterol. This delivery order represents a task order issued under Amerisourcebergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
Amerisourcebergen Drug Corp operates as a subsidiary of parent company Cencora, Inc. (doing business as Amerisourcebergen), a leading pharmaceutical distributor and healthcare solutions provider. The parent company holds its own significant IDC with the Defense Logistics Agency valued at up to $999,999,999.00 through December 31, 2031. Through these contract vehicles, Amerisourcebergen supplies an extensive range of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The competitively awarded delivery orders consistently feature firm fixed pricing and demonstrate the company's capability to fulfill diverse federal medical supply requirements across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F1T13?
SPE2DR26F1T13 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26F1T13 worth?
The government has obligated $105,362 on SPE2DR26F1T13.
Is contract SPE2DR26F1T13 an order under another contract?
Yes. SPE2DR26F1T13 is a delivery order under SPE2DR25D2205, an indefinite delivery contract.
Was contract SPE2DR26F1T13 competed?
The extent of competition for SPE2DR26F1T13 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award